Dialybrid secures €15 million series A round and announces successful first-in-human implant of novel Silkothane® Arteriovenous Graft for vascular access in hemodialysis

Trial StartpositiveSilkothane® Arteriovenous GraftPositive

AI Analysis

Summary

Dialybrid secured €15 million in Series A funding and announced a successful first-in-human implant of its Silkothane® Arteriovenous Graft for vascular access in hemodialysis patients.

Clinical Trial Data

Phase

first-in-human

Primary Endpoint

Met

Outcome Details

successful first-in-human implant

Importance:6/10

Sentiment:

0.80

vascular accesshemodialysismedical deviceSeries A fundingfirst-in-human

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on September 22, 2026 6:30 AM

Read Original